Q2-FY26 · Dr. Yasiri Raji
We reported revenue of 588 crores rupees 588 crores registering a healthy 16% growth yi. This was driven by a very strong performance of by of our nonGPL business which grew at by 39.7%.
ALIVUS / language trends
Read confidence between the lines.
Alivus Life Sciences · tone and specificity signals across the available quarters.
Research layer active
Language signals
What changed in management language.
tracked
Q2-FY26 · Dr. Yasiri Raji
Our EITA margin for the quarter was 33% up 480 bips YI.
Q2-FY26 · Dr. Yasiri Raji
We remain confident of sustaining margins at around 30% despite the absence of PLI benefits.
Q3-FY26 · Dr. Yaji
We reported our highest ever revenue of 673 crores registering a growth of 14.4% QoQ and 4.8% YoY.
Q3-FY26 · Dr. Yaji
Our CDMO segment has made a strong recovery delivering an exceptional performance in Q3 with revenue growth of 100% QoQ and 85.3% YoY.
Q3-FY26 · Tushar Mistri
We now guide the capex to be at around rupees 450 crores compared to our earlier items of 600 crores.
Q4-FY26 · Dr. Yasir Raji
We expect the contribution from the non-GPL business to continue to increase going forward.
Q4-FY26 · Dr. Yasir Raji
We remain confident in our ability to sustain EBITDA margins in the range of 30 to 32%.
Q4-FY26 · Dr. Yasir Raji
Maintaining a high quality business is a much bigger priority for Alivus. Growth will not be pursued at the cost of margins.